Erlend Skaga1, Marthe Andrea Skretteberg2, Tom Børge Johannesen3, Petter Brandal4, Einar O Vik-Mo1, Eirik Helseth1,2, Iver A Langmoen1,2. 1. Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Oslo, Norway. 2. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. 3. Department of Registration, Cancer Registry of Norway, Oslo, Norway. 4. Department of Oncology, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characteristics of the patients in a population considered either eligible or ineligible for trials is unknown. The generalizability of trial results is therefore also uncertain. METHODS: Using the Cancer Registry of Norway and the Brain Tumor Database at Oslo University Hospital, we tracked all patients within a well-defined geographical area with newly diagnosed GBM during the years 2012-2017. Based on data from these registries and the medical records, the patients were evaluated for trial eligibility according to criteria employed in recent phase III trials for GBM. RESULTS: We identified 512 patients. The median survival was 11.7 months. When we selected a potential trial population at the start of concurrent chemoradiotherapy (radiotherapy [RT]/ temozolomide [TMZ]) by the parameters age (18-70 y), passed surgery for a supratentorial GBM, Eastern Cooperative Oncology Group (ECOG) ≤2, normal hematologic, hepatic and renal function, and lack of severe comorbidity, 57% of the patients were excluded. Further filtering the patients who progressed during RT/TMZ and never completed RT/TMZ resulted in exclusion of 59% and 63% of the patients, respectively. The survival of patients potentially eligible for trials was significantly higher than of the patients not fulfilling trial eligibility criteria (P < .0001). CONCLUSIONS: Patients considered eligible for phase III clinical trials represent a highly selected minority of patients in a real-world GBM population.
BACKGROUND: The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characteristics of the patients in a population considered either eligible or ineligible for trials is unknown. The generalizability of trial results is therefore also uncertain. METHODS: Using the Cancer Registry of Norway and the Brain Tumor Database at Oslo University Hospital, we tracked all patients within a well-defined geographical area with newly diagnosed GBM during the years 2012-2017. Based on data from these registries and the medical records, the patients were evaluated for trial eligibility according to criteria employed in recent phase III trials for GBM. RESULTS: We identified 512 patients. The median survival was 11.7 months. When we selected a potential trial population at the start of concurrent chemoradiotherapy (radiotherapy [RT]/ temozolomide [TMZ]) by the parameters age (18-70 y), passed surgery for a supratentorial GBM, Eastern Cooperative Oncology Group (ECOG) ≤2, normal hematologic, hepatic and renal function, and lack of severe comorbidity, 57% of the patients were excluded. Further filtering the patients who progressed during RT/TMZ and never completed RT/TMZ resulted in exclusion of 59% and 63% of the patients, respectively. The survival of patients potentially eligible for trials was significantly higher than of the patients not fulfilling trial eligibility criteria (P < .0001). CONCLUSIONS: Patients considered eligible for phase III clinical trials represent a highly selected minority of patients in a real-world GBM population.
Authors: Susan M Chang; Sharon L Reynolds; Nicholas Butowski; Kathleen R Lamborn; Jan C Buckner; Richard S Kaplan; Darell D Bigner Journal: Neuro Oncol Date: 2005-10 Impact factor: 12.300
Authors: Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen Journal: Neuro Oncol Date: 2019-09-06 Impact factor: 12.300
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Edward R Laws; Ian F Parney; Wei Huang; Fred Anderson; Angel M Morris; Anthony Asher; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew Sloan; Mitchel S Berger; Susan Chang Journal: J Neurosurg Date: 2003-09 Impact factor: 5.115
Authors: Ulrich Herrlinger; Theophilos Tzaridis; Frederic Mack; Joachim Peter Steinbach; Uwe Schlegel; Michael Sabel; Peter Hau; Rolf-Dieter Kortmann; Dietmar Krex; Oliver Grauer; Roland Goldbrunner; Oliver Schnell; Oliver Bähr; Martin Uhl; Clemens Seidel; Ghazaleh Tabatabai; Thomas Kowalski; Florian Ringel; Friederike Schmidt-Graf; Bogdana Suchorska; Stefanie Brehmer; Astrid Weyerbrock; Miriam Renovanz; Lars Bullinger; Norbert Galldiks; Peter Vajkoczy; Martin Misch; Hartmut Vatter; Moritz Stuplich; Niklas Schäfer; Sied Kebir; Johannes Weller; Christina Schaub; Walter Stummer; Jörg-Christian Tonn; Matthias Simon; Vera C Keil; Michael Nelles; Horst Urbach; Martin Coenen; Wolfgang Wick; Michael Weller; Rolf Fimmers; Matthias Schmid; Elke Hattingen; Torsten Pietsch; Christoph Coch; Martin Glas Journal: Lancet Date: 2019-02-14 Impact factor: 79.321
Authors: Linda M Liau; Keyoumars Ashkan; David D Tran; Jian L Campian; John E Trusheim; Charles S Cobbs; Jason A Heth; Michael Salacz; Sarah Taylor; Stacy D D'Andre; Fabio M Iwamoto; Edward J Dropcho; Yaron A Moshel; Kevin A Walter; Clement P Pillainayagam; Robert Aiken; Rekha Chaudhary; Samuel A Goldlust; Daniela A Bota; Paul Duic; Jai Grewal; Heinrich Elinzano; Steven A Toms; Kevin O Lillehei; Tom Mikkelsen; Tobias Walbert; Steven R Abram; Andrew J Brenner; Steven Brem; Matthew G Ewend; Simon Khagi; Jana Portnow; Lyndon J Kim; William G Loudon; Reid C Thompson; David E Avigan; Karen L Fink; Francois J Geoffroy; Scott Lindhorst; Jose Lutzky; Andrew E Sloan; Gabriele Schackert; Dietmar Krex; Hans-Jorg Meisel; Julian Wu; Raphael P Davis; Christopher Duma; Arnold B Etame; David Mathieu; Santosh Kesari; David Piccioni; Manfred Westphal; David S Baskin; Pamela Z New; Michel Lacroix; Sven-Axel May; Timothy J Pluard; Victor Tse; Richard M Green; John L Villano; Michael Pearlman; Kevin Petrecca; Michael Schulder; Lynne P Taylor; Anthony E Maida; Robert M Prins; Timothy F Cloughesy; Paul Mulholland; Marnix L Bosch Journal: J Transl Med Date: 2018-05-29 Impact factor: 5.531
Authors: Stephen J Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q Lee; Gavin P Dunn; Evanthia Galanis; Susan M Chang; Louis Burt Nabors; Manmeet S Ahluwalia; Roger Stupp; Minesh P Mehta; David A Reardon; Stuart A Grossman; Erik P Sulman; John H Sampson; Simon Khagi; Michael Weller; Timothy F Cloughesy; Patrick Y Wen; Mustafa Khasraw Journal: Clin Cancer Res Date: 2022-02-15 Impact factor: 13.801